Noninvasive prenatal diagnosis for single gene disorders

Area of Science:

• Reproductive Medicine
• Genetics
• Molecular Diagnostics

Background:

• Cell-free DNA (cfDNA) in maternal plasma is a known biomarker.
• Noninvasive prenatal diagnosis (NIPD) for single gene disorders faces technological and validation challenges.
• Clinical utility of NIPD is progressing, with ongoing research into various analytical methods.

Purpose of the Study:

• To review the current state and emerging technologies for noninvasive prenatal diagnosis of single gene disorders.
• To highlight the feasibility and challenges of clinical application.
• To discuss the ethical and social implications of advancing NIPD.

Main Methods:

• Analysis of cfDNA using digital PCR, next-generation sequencing, and relative haplotype dosage.
• Investigation of circulating fetal cells and transcervical trophoblast cells as alternative sources.
• Review of emerging technical approaches and validation studies.

Main Results:

• Multiple technical approaches for cfDNA analysis are being published, demonstrating feasibility.
• Digital PCR, next-generation sequencing, and relative haplotype dosage are common assay development techniques.
• Ethical and social issue studies are generally positive but note concerns regarding routine prenatal testing.

Conclusions:

• Continued research is essential to broaden patient access to NIPD for single gene disorders.
• The impact of advanced single-cell analysis technologies on NIPD remains to be determined.
• Increased availability of NIPD for diverse conditions will necessitate addressing new ethical questions.